Biotherapy Development president Takeshi Toyoda claims the popsicles 'will remain almost the same even if exposed to the hot air from a dryer.'
Wang, State Key Laboratory of
Biotherapy, West China Hospital, West China Medical School, Sichuan University, Gaopeng Street, Keyuan Road 4, Chengdu, 610041, China.
Williams et al., "A phase I trial of [sup.90]Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies," Cancer
Biotherapy and Radiopharmaceuticals, vol.
Dubois, " Study of monoglutathionyl conjugates TC-99M-sestamibi and TC-99M-tetrofosmin transport mediated by the multidrug resistance-associated protein isoform 1 in glioma cells," Cancer
Biotherapy & Radiopharmaceuticals, vol.
Abedi, "Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor," Cancer
Biotherapy and Radiopharmaceuticals, vol.
They discuss progress in China in cancer
biotherapy and chemotherapeutic drug research; cancer targeting gene-viro-therapy; the relationship between antiproliferative activities and class I MHC surface expression of mouse interferon proteins on B16-F10 melanoma cells; mitotic regulator Hec1 as a potential target for cancer therapy; advances in liposome-based targeted gene therapy; rewiring the intracellular signaling network in cancer; and the research and development of highly potent antibody-based drug conjugates and fusion proteins for cancer therapy.
We believe that
biotherapy of such ulcers will be a challenge but will also offer hope to wound researchers in the coming decades," they said.
Contributions go to research including personalized therapy, cell therapy,
biotherapy, and tumor growth and preservation for research.
In conclusion, a suggested arthritis screening profile consisting of the acute phase reactant CRP, circulating cytokines (IFN-[gamma], IL-1[beta], IL-1Ra, TNF, GM-CSF, and VEGF), autoantibodies RF and anti-CCP and HLA-DRB1 high-resolution molecular typing shows promise to identify those patients who may benefit from a more aggressive treatment regimen or immediate biological
biotherapy. The cost of such an extensive panel may be justified by the benefits to the patients and management of disease burden in the long term.
"Several studies demonstrated the therapeutic potential of this strategy, but we still had to find techniques that were reliable in human beings", explains Bruno Pitard, Director of the
Biotherapy Innovations team at the Institut du thorax (CNRS/Inserm/University of Nantes).
Theranostic testing can be combined with targeted
biotherapy in an effort to predict or assess a patient's response by measuring one or more biomarkers.